Broad Spectrum Antiviral Therapy can Supersede Vaccination Strategy for Combating COVID-19 Pandemic
Journal: Medical Journal of Clinical Trials & Case Studies (Vol.5, No. 4)Publication Date: 2021-07-21
Authors : Diwan A Chakraborty A Tatake J Barton R Chiniga V Pandey R Holkar P Arora V Thakur Y Holkar N; Pond B;
Page : 1-21
Keywords : COVID-19; SARS-CoV-2; Therapy; Vaccine; Antibodies; Plasma Therapy; Antiviral; Remdesivir; Chloroquine/ Hydroxychloroquine; Nanoviricides; Venus-Flytrap;
Abstract
As of today seven coronaviruses were identified to infect humans, out of which only 4 of them belongs to beta family of coronavirus, like HCoV-HKU1, SARS-CoV-2, MERS-CoV and SARS-CoV. SARS family viruses were known to cause severe respiratory disease in humans. SARS-CoV-2 has recently considered as a pandemic with over 100 M confirmed cases and over 1.5 M death worldwide. Vaccines and antibodies appeared as record pace. However, generation of variants has already been demonstrated as an escape of virus from a particular vaccine therapy. Therefore, a broad-spectrum anti-CoV therapies should be emphasized.
Other Latest Articles
- Broad Spectrum Antiviral Therapy can Supersede Vaccination Strategy for Combating COVID-19 Pandemic
- A Randomized, Comparative Clinical Trial to Evaluate Efficacy and Safety of PNB-001 as Immune Modulator in Moderate COVID-19 Patients
- Post-Acute-COVID-19-Illness Cardiovascular Sequelae
- Thanatophoric Dysplasia
- Efficacy of Rituximab Therapy for Oculomotor Nerve Palsy and Vision Loss Due to Granulomatous Polyangiitis
Last modified: 2023-07-19 18:56:05